Items where Author is "von Moos, R."

2015

Köberle, D. and Betticher, D. C. and von Moos, R. and Dietrich, D. and Brauchli, B. and Baertschi, D. and Matter, K. and Winterhalder, R. and Borner, M. and Anchisi, S. and Moosmann, P. and Kollar, A. and Saletti, P. and Roth, A. and Frueh, M. and Kueng, M. and Popescu, R. A. and Schacher, S. and Hess, V. and Herrmann, R.. (2015) Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of Oncology, 26 (4). pp. 709-714.

2011

Rochlitz, C. and Ruhstaller, T. and Lerch, S. and Spirig, C. and Huober, J. and Suter, T. and Buhlmann, M. and Fehr, M. and Schonenberger, A. and von Moos, R. and Winterhalder, R. and Rauch, D. and Muller, A. and Mannhart-Harms, M. and Herrmann, R. and Cliffe, B. and Mayer, M. and Zaman, K.. (2011) Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer : a multicenter, single-arm phase II trial (SAKK 24/06). Annals of oncology, Vol. 22, H. 1. pp. 80-85.

Koeberle, D. and Ruhstaller, T. and Jost, L. and Pagani, O. and Zaman, K. and von Moos, R. and Oehlschlegel, C. and Crowe, S. and Pilop, C. and Thuerlimann, B. and Swiss Grp Clinical Canc Res Sakk, . (2011) Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer : a proof-of-concept trial (SAKK 23/03). Endocrine related cancer, Vol. 18, H. 2. pp. 257-264.

2009

Ribi, K. and Koeberle, D. and Schuller, J. C. and Honegger, H. and Roth, A. and Hess, V. and Moosmann, P. and von Moos, R. and Borner, M. and Lombriser, N. and Pestalozzi, B. and Ruhstaller, T.. (2009) Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Vol. 17. pp. 1109-1116.

Ruhstaller, T. and Widmer, L. and Schuller, J. C. and Roth, A. and Hess, V. and Mingrone, W. and von Moos, R. and Borner, M. and Pestalozzi, B. C. and Balmermajno, S. and Köberle, D. and Terraciano, L. and Schnider, A. and Bodis, S. and Popescu, R.. (2009) Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 20. pp. 1522-1528.

2008

Thürlimann, B. and Bonnefoi, H. and Cameron, D. and Goldhirsch, A. and Herrmann, R. and Monnerat, C. and von Moos, R. and Pagani, O. and Perey, L. and Pestalozzi, B. and Rochlitz, C. and Suter, T.. (2008) Adjuvant therapy of HER2-positive breast cancer with trastuzumab. Senologie, Vol. 5. pp. 1-3.

Montemurro, M. and Dirnhofer, S. and Vorner, M. and Burkhard, R. and Demartines, N. and Furrer, M. and Guillou, L. and Kettelhack, Ch and Knüsli, C. and Langer, I. and Metzger, U. and Redaelli, C. and Tornillo, L. and von Flüe, M. and von Moos, R. and Leyvraz, S.. (2008) Diagnose und Behandlung von gastrointestinalen Strumatumoren (GIST) in der Schweiz. Empfehlungen einer multidisziplinären Expertengruppe. Schweizerisches Medizin-Forum, Vol. 8. pp. 544-549.

Koeberle, D. and Burkhard, R. and von Moos, R. and Winterhalder, R. and Hess, V. and Heitzmann, F. and Ruhstaller, T. and Terraciano, L. and Neuweiler, J. and Bieri, G. and Rust, C. and Toepfer, M.. (2008) Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. British journal of cancer, Vol. 98, no. 7. pp. 1204-1209.

von Moos, R. and Caspar, C. B. and Thürlimann, B. and Angst, R. and Inauen, R. and Greil, R. and Bergstrom, B. and Schmieding, K. and Pecherstorfer, M.. (2008) Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min : a randomized, open-label study. Annals of oncology, Vol. 19, H. 7. pp. 1266-1270.